Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With TARGIN in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)

Next Previous
X
Search
Trial Profile

An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With TARGIN in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxycodone/naloxone (Primary)
  • Indications Pain
  • Focus Adverse reactions
  • Acronyms GLORY
  • Sponsors Mundipharma International

    • Most Recent Events

    • 07 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 Nov 2013 Planned End Date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top